Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients

Little is known about the influence of Riluzole on serum neurofilament light chain (sNfL) levels, a biomarker of prognosis in amyotrophic lateral sclerosis (ALS), and variations with time of sNfL concentrations are controversial.

[1]  P. Avoni,et al.  Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study , 2021, Frontiers in Aging Neuroscience.

[2]  G. Soraru',et al.  Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers , 2020, Molecular neurodegeneration.

[3]  A. Winkler,et al.  Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  Timothy A. Miller,et al.  Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2020, The New England journal of medicine.

[5]  P. van Damme,et al.  Amyotrophic lateral sclerosis: a clinical review , 2020, European journal of neurology.

[6]  M. Benatar,et al.  Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS , 2020, Neurology.

[7]  S. Lehmann,et al.  Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis , 2020, European journal of neurology.

[8]  F. Verde,et al.  Neurochemical biomarkers in amyotrophic lateral sclerosis. , 2019, Current opinion in neurology.

[9]  K. Blennow,et al.  NFL is a marker of treatment response in children with SMA treated with nusinersen , 2019, Journal of Neurology.

[10]  J. Kassubek,et al.  Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  P. Andersen,et al.  Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion , 2018, Annals of neurology.

[12]  L. Wilkins.  Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis , 2015, Neurology.

[13]  P. Andersen,et al.  Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  Bernhard Hemmer,et al.  Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies , 2011, Multiple sclerosis international.

[15]  David M. Rissin,et al.  Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.

[16]  T. Hanafusa,et al.  Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.

[17]  O. Hardiman,et al.  Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. , 2000, Archives of neurology.

[18]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[19]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.